New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.
News, blogs and podcasts
Latest articles
‘Trojan horse’ treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Have your say on NICE’s adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
Changes to NICE’s cost-effectiveness thresholds take effect
NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.
Latest in-depth
From fear to freedom
NICE-recommended healthtech found the cause of Peter’s stroke. Read his story and discover how our guidance is helping life-changing innovations reach the patients who need them.
From surviving to thriving
Hear from Ammaarah as she explains the remarkable impact hybrid closed loop technology has had on her life and how its successful rollout is the model we want to replicate.
Latest blogs
MHRA-NICE pathway opens for business – everything you need to know to get started
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
Better data for better decisions
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
Latest podcasts
Backing the healthtech that changes lives
How NICE guidance is accelerating access to innovative migraine treatments
